All In Biotech

Drug Trial Radar · NCT05009836

Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib + Osimertinib Versus Placebo + Osimertinib as the First Line Therapy for Patients With EGFRm+/MET+ NSCLC

Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 412 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

412

Planned (sponsor's estimate)

Start

Sep 6, 2021

Primary completion

May 30, 2028

Study completion May 30, 2028

Sponsor

Lead sponsor
HutchmedIndustry
Sponsor type
Industry
First posted
Aug 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase III Clinical Study on Savolitinib Combined with Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • SavolitinibDrug

    Savolitinib 600 mg or 400 mg daily (including 600/400 mg QD or 300/200 mg BID) orally

  • PlaceboDrug

    Placebo 600 mg or 400 mg daily (including 600/400 mg QD or 300/200 mg BID) orally

  • OsimertinibDrug

    Osimertinib 80 mg QD orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFSTime frame: 17 months after the last patient enrolled

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Guangdong General Hospital

    Guangzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.